Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Current Scenario of HIV/AIDS, Treatment Options, and Major Challenges with Compliance to Antiretroviral Therapy.

Bhatti AB, Usman M, Kandi V.

Cureus. 2016 Mar 1;8(3):e515. doi: 10.7759/cureus.515. Review.

2.

Novel Time-Resolved Fluorescence Europium Nanoparticle Immunoassay for Detection of Human Immunodeficiency Virus-1 Group O Viruses Using Microplate and Microchip Platforms.

Haleyur Giri Setty MK, Liu J, Mahtani P, Zhang P, Du B, Ragupathy V, Devadas K, Hewlett IK.

AIDS Res Hum Retroviruses. 2016 Jun;32(6):612-9. doi: 10.1089/aid.2014.0351. Epub 2016 Mar 15.

PMID:
26978478
3.

HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs.

Tebit DM, Patel H, Ratcliff A, Alessandri E, Liu J, Carpenter C, Plantier JC, Arts EJ.

AIDS Res Hum Retroviruses. 2016 Jul;32(7):676-88. doi: 10.1089/AID.2015.0318. Epub 2016 Mar 16.

PMID:
26861573
4.

HIV-1 group O infection in Cameroon from 2006 to 2013: Prevalence, genetic diversity, evolution and public health challenges.

Villabona-Arenas CJ, Domyeum J, Mouacha F, Butel C, Delaporte E, Peeters M, Mpoudi-Ngole E, Aghokeng AF.

Infect Genet Evol. 2015 Dec;36:210-6. doi: 10.1016/j.meegid.2015.09.006. Epub 2015 Sep 11.

5.

Origin of the HIV-1 group O epidemic in western lowland gorillas.

D'arc M, Ayouba A, Esteban A, Learn GH, Boué V, Liegeois F, Etienne L, Tagg N, Leendertz FH, Boesch C, Madinda NF, Robbins MM, Gray M, Cournil A, Ooms M, Letko M, Simon VA, Sharp PM, Hahn BH, Delaporte E, Mpoudi Ngole E, Peeters M.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1343-52. doi: 10.1073/pnas.1502022112. Epub 2015 Mar 2.

6.

HIV epidemiology. The early spread and epidemic ignition of HIV-1 in human populations.

Faria NR, Rambaut A, Suchard MA, Baele G, Bedford T, Ward MJ, Tatem AJ, Sousa JD, Arinaminpathy N, Pépin J, Posada D, Peeters M, Pybus OG, Lemey P.

Science. 2014 Oct 3;346(6205):56-61. doi: 10.1126/science.1256739. Epub 2014 Oct 2.

7.

Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability.

Usach I, Melis V, Peris JE.

J Int AIDS Soc. 2013 Sep 4;16:1-14. doi: 10.7448/IAS.16.1.18567. Review.

8.

Non-M variants of human immunodeficiency virus type 1.

Mourez T, Simon F, Plantier JC.

Clin Microbiol Rev. 2013 Jul;26(3):448-61. doi: 10.1128/CMR.00012-13. Review.

9.

Noninvasive follow-up of simian immunodeficiency virus infection in wild-living nonhabituated western lowland gorillas in Cameroon.

Etienne L, Locatelli S, Ayouba A, Esteban A, Butel C, Liegeois F, Aghokeng A, Delaporte E, Mpoudi Ngole E, Peeters M.

J Virol. 2012 Sep;86(18):9760-72. doi: 10.1128/JVI.01186-12. Epub 2012 Jun 27.

10.

Efficient SIVcpz replication in human lymphoid tissue requires viral matrix protein adaptation.

Bibollet-Ruche F, Heigele A, Keele BF, Easlick JL, Decker JM, Takehisa J, Learn G, Sharp PM, Hahn BH, Kirchhoff F.

J Clin Invest. 2012 May;122(5):1644-52. doi: 10.1172/JCI61429. Epub 2012 Apr 16.

11.

Origins of HIV and the AIDS pandemic.

Sharp PM, Hahn BH.

Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006841. doi: 10.1101/cshperspect.a006841. Review.

12.

Lack of adaptation to human tetherin in HIV-1 group O and P.

Yang SJ, Lopez LA, Exline CM, Haworth KG, Cannon PM.

Retrovirology. 2011 Sep 28;8:78. doi: 10.1186/1742-4690-8-78.

13.

Phylodynamics of the HIV-1 CRF02_AG clade in Cameroon.

Faria NR, Suchard MA, Abecasis A, Sousa JD, Ndembi N, Bonfim I, Camacho RJ, Vandamme AM, Lemey P.

Infect Genet Evol. 2012 Mar;12(2):453-60. doi: 10.1016/j.meegid.2011.04.028. Epub 2011 May 4.

14.

Identification of new, emerging HIV-1 unique recombinant forms and drug resistant viruses circulating in Cameroon.

Ragupathy V, Zhao J, Wood O, Tang S, Lee S, Nyambi P, Hewlett I.

Virol J. 2011 Apr 23;8:185. doi: 10.1186/1743-422X-8-185.

15.

Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors.

Tebit DM, Lobritz M, Lalonde M, Immonen T, Singh K, Sarafianos S, Herchenröder O, Kräusslich HG, Arts EJ.

J Virol. 2010 Oct;84(19):9817-30. doi: 10.1128/JVI.00991-10. Epub 2010 Jul 14.

16.

High GUD incidence in the early 20 century created a particularly permissive time window for the origin and initial spread of epidemic HIV strains.

de Sousa JD, Müller V, Lemey P, Vandamme AM.

PLoS One. 2010 Apr 1;5(4):e9936. doi: 10.1371/journal.pone.0009936.

17.

Origin and biology of simian immunodeficiency virus in wild-living western gorillas.

Takehisa J, Kraus MH, Ayouba A, Bailes E, Van Heuverswyn F, Decker JM, Li Y, Rudicell RS, Learn GH, Neel C, Ngole EM, Shaw GM, Peeters M, Sharp PM, Hahn BH.

J Virol. 2009 Feb;83(4):1635-48. doi: 10.1128/JVI.02311-08. Epub 2008 Dec 10.

18.

Difficulties in diagnosing group o human immunodeficiency virus type 1 acute primary infection.

Henquell C, Jacomet C, Antoniotti O, Chaib A, Regagnon C, Brunet S, Peigue-Lafeuille H, Barin F.

J Clin Microbiol. 2008 Jul;46(7):2453-6. doi: 10.1128/JCM.02217-07. Epub 2008 May 14.

19.

Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.

Buonaguro L, Tornesello ML, Buonaguro FM.

J Virol. 2007 Oct;81(19):10209-19. Epub 2007 Jul 18. Review. No abstract available.

20.

Group o human immunodeficiency virus type 1 infection that escaped detection in two immmunoassays.

Zouhair S, Roussin-Bretagne S, Moreau A, Brunet S, Laperche S, Maniez M, Barin F, Harzic M.

J Clin Microbiol. 2006 Feb;44(2):662-5.

Items per page

Supplemental Content

Write to the Help Desk